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Cardiac rehabilitation (CR) reach is minimal globally, primarily due to financial factors. This 
study characterized CR funding sources, cost to patients to participate, cost to programs to serve 
patients, and the drivers of these costs. 
Methods: 
In this cross-sectional study, an online survey was administered to CR programs globally. 
Cardiac associations and local champions facilitated program identification. Costs in each 
country were reported using purchasing power parity (PPP). Results were compared by World 
Bank country income classification using generalized linear mixed models.  
Results: 
111/203 (54.68%) countries in the world offer CR, of which data were collected in 93 (83.78% 
country response rate; N=1082 surveys, 32.0% program response rate). CR was most-often 
publicly funded (more in high-income countries [HICs]; p<.001), but in 60.20% of countries 
patients paid some or all of the cost. Funding source impacted capacity (p=.004), number of 
patients per exercise session (p<.001), personnel (p=.037), and functional capacity testing 
(p=.039). The median cost to serve 1 patient was $945.91PPP globally. In low and middle-
income countries (LMICs), exercise equipment and stress testing were perceived as the most 
expensive delivery elements, with front-line personnel costs perceived as costlier in HICs 
(p=.003). Modifiable factors associated with higher costs included CR team composition 
(p=.001), stress testing (p=.002) and telemetry monitoring in HICs (p=.01), and not offering 
alternative models in LMICs (p=.02).  
Conclusions:  
Too many patients are paying out-of-pocket for CR, and more public funding is needed. Lower-
cost delivery approaches are imperative, and include walk tests, task-shifting, and intensity 








Cardiovascular diseases (CVD) are among the leading burdens of disease and disability 
globally[1]. In addition to health impacts, CVD also poses a major economic burden on patients, 
society, and healthcare systems. On a global level, it is predicted that by 2030, the total cost of 
CVD will rise to a staggering $1,044 billion US dollars (USD) (from $863 billion USD in 
2010)[2]. Evidence suggests that CVD pushes approximately 10% of affected families into 
poverty in low and middle-income countries (LMICs) where the epidemic of CVD is at its 
worst[3].   
Cardiac rehabilitation (CR) is a chronic disease management program that successfully 
prolongs quality and quantity of life (e.g., 25% reductions in cardiovascular mortality[4]), and 
hence clinical practice guidelines recommend CVD patients participate[5,6]. The cost-
effectiveness of CR is well-established across many contexts and perspectives[7–10]. CR 
participation is associated with return to work and healthcare avoidance. CR costs much less than 
percutaneous coronary intervention, yet equivalent outcomes are often achieved, supporting 
affordability[11]. 
Unfortunately, CR is grossly under-used[11]. While there are multiple factors at play at 
the healthcare system (e.g., capacity), provider (e.g, lack of referral, lack of trained personnel to 
deliver CR), and patient (e.g., lack of awareness) levels[12], arguably the primary reason is 
financial. Most programs are under-resourced to deliver comprehensive evidence-based services. 
Indeed, surveys of CR programs in Australia and New Zealand[13], China[14], Japan[15], 
Scotland[16], Spain[17], Latin America and the Caribbean[18–20], the Arab Region as well as 





A major issue affecting financial viability of CR is whether services are reimbursed or 
“covered” by government or private insurers, among other sources. There is wide variation 
around the world in reimbursement sources however, and in many countries patients must pay 
out-of-pocket (OOP). Recently, the International Council of Cardiovascular Prevention and 
Rehabilitation (ICCPR) surveyed CR leaders around the globe regarding reimbursement sources 
(respondents were asked to check all that apply); 61% reported the government, 55% reported 
patients pay OOP, and 52% reported insurance companies[22]. Clearly too many patients pay 
OOP for CR, and thus a better understanding of these costs is needed, given the likely impacts on 




Moreover, while financial resources are the major cause of under-utilization, little is 
known about the costs to deliver (quality) CR around the world. While there is variability, most 
patients attend supervised programs located in clinical centres[27]; on average patients exercise 
on site 2-3 times per week for 5 months[28]. Most programs are staffed by a multi-disciplinary 
team, to ensure competent delivery of all core components for secondary prevention[29]. Hence, 
delivering the traditional model of CR carries with it costs associated with personnel, exercise 
equipment and other supplies, space and other operating costs[24,25,30].  
In only 14 (12.6%) of the 111 countries known to offer CR globally[31] are the costs to 
run a program per patient known, at a median of $884 USD (2016 PPP) in high-income countries 
(HICs)[32]. Where assessed, delivery costs were generally higher in private versus public 
healthcare systems. Moreover, CR is delivered at much lower cost in LMICs than in HICs, and 
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what evidence is available suggests equivalent benefits are achieved[33]. Other than these, 
factors affecting delivery costs have never been examined to our knowledge. 
Therefore, the objectives of this study were to characterize: (1) funding source, and (1b) 
the proportion of the program cost as well as (1c) direct cost, to patients where they pay for CR; 
and (2) the estimated cost to CR programs to provide service to 1 patient, (2b) which aspects of 
program delivery are perceived as most expensive, and (2c) whether cost varies by funding 
source in countries around the globe that deliver CR. The association of: (3i) a program’s patient 
capacity per year, (ii) the number and nature of healthcare professionals on the CR team, (iii) the 
number of patients served per exercise session (including staff-to-patient ratio), (iv) the number 
and nature of core components the program delivers; (v) the dose of CR (i.e., duration of 
program in weeks x the frequency of sessions per week); (vi) the equipment/resources the 
program has (e.g., exercise equipment, supplies for cardiovascular risk assessment) including 
whether patients are monitored during exercise using telemetry, and (vii) whether the program 
offers alternative CR models (i.e., home or community-based) to both funding source (1) and 
cost to treat 1 patient (2) will also be explored, to understand factors that impact CR delivery 
costs. Finally, (4) the degree to which financial and other resources serve as barriers to CR 
delivery will be described. Each will be compared by country income classification (i.e., HICs vs 
LMICs), and described in all countries of the world where CR is offered.   
METHODS 
 
Design & Procedure 
 
This research was observational and cross-sectional in design; detailed methods are 
reported elsewhere[31]. In brief, countries where CR services were available were identified first 
through previous reviews[11,23]. In countries where CR services were not suspected to be 
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available, the internet was searched and major CR and cardiology societies were contacted to 
identify any programs or verify lack thereof.  
For each country identified to offer CR, first available CR or cardiac societies leadership 
was contacted, and if there was no society available or response, “champions” were identified. 
Identified leaders were sent an e-mail requesting their collaboration to administer the survey to 
each program in their country.  
The most responsible clinician at each program was emailed with the request to complete 
the survey. Informed consent was secured through an online form. The survey was administered 
through REDCap, with data collection occurring from June 2016 to July 2017. Contacts were 
sent 2 e-mail reminders, at 2 week intervals.  
Sample 
 
 The sample consisted of all CR programs identified in the world, that offer services to 
patients following an acute cardiac event or hospitalization (i.e., Phase II). This includes 
residential programs[34]. The inclusion criteria were CR programs that offered: (1) initial 
assessment, (2) structured exercise, and (3) at least one other strategy to control CV risk factors.  
Measures 
 
Development of the survey is described in detail elsewhere[21]. In short, items were 
based on previous national/regional CR programs surveys (e.g.,[19,27,35]). Most items had 
forced-choice response options, and skip-logic was used to obtain more detail where applicable. 
The survey is available elsewhere[31]. 
Respondents were asked to state their country. These were also categorized as high vs 
LMIC based on the World Bank classifications (http://data.worldbank.org/country). 
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Cost-related items used herein included: who pays for CR (i.e., public sources such as 
government, private sources such as insurance companies or patients [and the amount they pay], 
or other sources), the cost to the CR program to serve one patient if they complete the program , 
perceived expense of various CR program elements, and resource-related barriers to CR delivery 
(the latter 2 were rated on a 5-point Likert-type scale). The drivers of costs were also assessed, 
including: annual patient capacity, types of personnel on the CR team, staff-to-patient ratio 
during exercise sessions, and telemetry monitoring of patients, core components delivered, dose 
and alternative model delivery (i.e., home and community-based).  
Costs were reported using purchasing power parity (PPP), which is a widely used metric 
to standardize and compare countries’ currencies (i.e., equilibrium using a “basket of goods” 
approach). PPPs (2016 $USD) for CR costs in each country were computed using a cost 
conversion tool developed by the Cochrane Economic group 
(http://eppi.ioe.ac.uk/costconversion/default.aspx).  
Data analysis  
 
SPSS version 24 was used for analysis[36]. All initiated surveys were included. The 
number of responses for each question varied due to missing data (e.g., respondent did not 
answer a question due to lack of willingness or potential inapplicability, use of skip logic); for 
descriptive analyses, percentages were computed with the denominator being the number of 
responses for a specific item.  
 Descriptive statistics were applied for all closed-ended items in the survey (i.e., objective 
1). All open-ended responses were coded / categorized. Associations were first tested on a 
univariate basis, using chi-square, t-tests, analysis of variance or correlations as appropriate.  
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Costs and funding sources were then compared by World Bank country income 
classification, using generalized linear mixed models to take into consideration the multi-level 
nature of the data, to handle missing data and different distributions of the dependent variables. 




As reported elsewhere,[31] there were 111/203 (54.68%) countries in the world with CR, of 
which data were collected in 93 (83.78%). The number of responses (mean=9.74±17.26/ 
country), and response rate (32.07% overall) by country are also reported there. The total sample 
size was N=1082 surveys.  
Cardiac Rehabilitation Funding Sources 
 
CR funding source is shown by country in Figure 1. Overall, in 46 (49.46%) countries CR was 
most often paid by public sources (i.e., government, hospital), in 22 (23.66%) countries CR was 
paid by private sources (i.e., patients [n=22, 100.00%] or private healthcare insurance [n=12, 
54.54%]), and in 25 (26.88%) countries CR was paid by a combination of these sources. Some 
respondents also listed other sources, which included research (n=8 programs), 
fundraising/charity foundations (n=4), and veteran services (n=3).  
CR was significantly more often paid by public (n=489, 66.40%) sources in HICs than in 
LMICs (n=103, 31.70%, p<0.001). Accordingly, CR was less often paid by private (n=87, 
11.80%) and hybrid (n=161, 21.80%) sources in HICs than in LMICs (n=115, 35.30%; p<0.001; 
and n=107, 33.10%; p<0.001 respectively).  
 For the countries where patients paid some or all of the program cost (n=56, 60.20%), the 
mean proportion of the program cost and the amount they paid are shown in Table 1. Patients in 
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Kenya and the Philippines paid all of the cost in most programs; patients pay all the cost in some 
programs in Greece, Pakistan, Peru and New Zealand. The cost to the patient was the highest in 
the following countries (PPP2016): Greece, Spain and Mexico (as well as Tunisia, but with only 
1 response caution is warranted). The proportion of the program that patients paid (p=0.19) nor 
the direct cost to patients (where they pay) for CR (p=0.79) were not significantly different in 
HICs than in LMICs. 
 Table 2 shows aspects of CR programs that are associated with funding source. As 
shown, program capacity (greater with hybrid sources), healthcare providers on team (greater 
with public than private funding), individual consult with physicians (greater with private 
funding), cardiopulmonary stress testing (greater with private funding), and patients per exercise 
session (greater with public and hybrid than private funding) varied significantly by funding 
source. When testing each of the 10 core components individually, tobacco cessation (p<0.001), 
return-to-work counselling (p=0.02), and patient education (p<.01) were significantly more-
commonly offered with public funding. While funding source was not associated with delivery 
of CR in any alternative setting, programs with public funding more often offered community-
based CR specifically than privately-funded ones (p=.03). No other associations were observed. 
Finally, Table 2 also shows that program capacity (higher where patients paid), the number of 
healthcare providers on the CR team (lower), and number of core components delivered (lower 
where patients paid) were also significantly different based on whether patients paid for at least 
some of program costs or not.  
Costs to Deliver CR 
 
 The estimated cost to deliver a full CR program to one patient is shown in Table 1. This 
did not differ significantly in LMICs versus HICs. Costs were highest in the following HICs: 
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Bermuda, Austria, United States; costs were lowest in Chile, Uruguay and Singapore. Costs were 
highest in the following LMICs: Macedonia, Dominican Republic, and Venezuela; costs were 
lowest in Cuba, Pakistan and Indonesia.  
 The elements of CR that contribute to these costs are shown in Supplementary Table 1. 
As shown, in HICs, front-line personnel and exercise stress testing were perceived as most 
expensive and in LMICs, exercise equipment and exercise stress testing were perceived as most 
expensive. Front-line personnel was considered significantly more expensive in HICs than 
LMICs (p<0.01); no other differences were observed.   
 Drivers of costs in HICs and LMICs are shown in Table 3. In HICs, program delivery  
costs significantly varied by funding source (i.e., higher with public and hybrid than private, and 
no patient finding versus any), were significantly higher with greater program capacity (and 
volume; data not shown), more providers on the healthcare team, higher where there was a 
physician on the CR team and patients had an individual consult with said physician, patients 
undergo cardiopulmonary stress tests, more core components are delivered, and patients are 
monitored with telemetry during exercise. In LMICs, higher program delivery costs were 
similarly associated with greater program capacity and with a greater number of providers on the 
healthcare team (trend for physicians specifically), but also with fewer patients per exercise 
session, and were significantly lower where programs offered alternative CR models (e.g., 
unsupervised). There was only a trend for funding source. 
Degree to Which Financial Resources Are Barriers to Cardiac Rehabilitation Delivery  
Finally, the perceived degree to which financial factors impede greater CR provision is 
reported by country[37] and by country income classification elsewhere[38]. When compared by 
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funding sources, human resources, space and equipment were greater delivery constraints with 
public funding compared to private funding (Supplementary Figure 1).  
DISCUSSION 
 
 CR funding and costs have been characterized globally for the first time herein. Of the 
countries with CR in the world (just over half), CR was funded from public sources solely in 
half, and this was more common in HICs (consistent with the fact that there is more public 
funding of health systems in HICs than LMICs[39]). Funding source impacted delivery costs, 
program capacity, patients per session, number and nature of healthcare providers on the team, 
and types of functional testing used. Moreover, some key CR components that would likely 
result in greater return-on-investment and downstream cost-savings (e.g., return-to-work and 
tobacco cessation counselling) were significantly more-commonly offered with public funding. 
CR resource availability, investment and care quality should not be impacted by funding source.  
In almost 2/3rds of the countries with CR, patients are paying for some or all of their CR 
programs OOP (on average 50% of the program cost or over 600PPP/$USD2016). This would 
lead to greater under-utilization. Given more patients in LMICs pay OOP than HICs, yet there is 
no significant difference in the proportion of the program costs paid or the amount in LMICs vs 
HICs (which likely reflects the fact that healthcare is more expensive in HICs[39]), this 
represents an especially heavy burden on patients in LMICs where economic well-being is 
significantly lower.  
The estimated cost to deliver CR to 1 patient, which should indeed be considered a gross 
estimate at this stage, was consistent in high LMICs (~$1500 2016PPP). Whether this represents 
a sufficient investment for effective CR remains to be established. These costs varied in relation 
to CR personnel composition, including physicians who are generally more expensive. 
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Cardiopulmonary stress testing and telemetry monitoring increased costs in HICs and alternative 
models reduced them in LMICs. The main costs associated with CR delivery were for exercise 
equipment, human resources and exercise stress testing, with most of these factors impeding CR 
delivery to a much greater degree in programs with some public funding. In LMICs, higher 
volume of patients per exercise session was associated with cost efficiencies.  
The $1500PPP cost to deliver CR is considerably lower than percutaneous 
intervention[40,41], which is sometimes performed without benefit when compared to optimal 
medical therapy. Moreover CR results in less healthcare utilization and more return-to-work, 
which further economically benefits society, adding further value to the low delivery cost. The 
only other available data on overall program costs[32] stem from the HICs of Canada ($884 
2016USDPPP)[25] and Australia ($1312 2016USDPPP)[24]. In the former, while human 
resource and equipment costs were high, space figured more prominently, as it did in the 
Australian study (although they considered some unit costs not assessed herein such as 
“administration” and “technology” which should be considered in future research). The available 
literature on CR personnel costs specifically is reviewed elsewhere[32]. Given the multi-
component nature of CR, and hence the multiple disciplines required to deliver it 
comprehensively, personnel costs are understandably quite high. There is wide variation in the 
staffing complement of CR programs (as well as country norms[31]; e.g., more nurse-led 
programs in Australia vs more physician-led programs in the United States), as well as program 
policies around staff-to-patient ratios during exercise for safety[21,42,43]; correspondingly 
overall costs to programs would vary. In LMICs, exercise equipment is considered the most 
expensive aspect of program delivery. As per the International Council of Cardiovascular 
Prevention and Rehabilitation (ICCPR) consensus statement on CR delivery in low-resource 
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setting, low-cost alternatives for exercise equipment are put forward[44,45], which should be 
seriously considered based on these findings.  
In many LMICs (55.32% of those with CR), the cost of CR delivery is higher than the 
mean health expenditure per capita (although we concede this is a crude comparison, but it does 
reflect affordability and relative investment). This would be an even higher percentage if we 
considered revascularization, yet we would not argue it should not be delivered, and therefore we 
need to consider how CR can be delivered in a safe, high-quality manner while containing costs. 
In addition to the suggestions to keep costs down in ICCPR’s consensus statement[44,45] and 
our previous review[32], based on the findings herein, strategies to reduce costs that should be 
tested include task-shifting to less expensive personnel (e.g., community healthcare workers), 
using physicians for consultation purposes as needed only, using a cheaper functional test than a 
cardiopulmonary stress test such as a 6 minute walk or shuttle walk test[46], exercising more 
patients per session, delivering exercise through non-equipment-based modalities, and not 
monitoring patients with telemetry during exercise unless they are established as high-risk. But 
more research needed as we do not know how these factors may impact program quality or 
safety. 
Limitations 
Caution is necessary when interpreting the findings, particularly due to limits on 
generalizability. Firstly, response rates to online surveys are notoriously low. While 
generalizability to countries with CR can be considered high, extrapolation within some 
countries should be undertaken with caution due to low program response rates. Second, it may 
not have been possible to identify programs, especially in LMICs where they may not have a 
website or have published any research, and in countries where no society or champion was 
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identified. Therefore, extra caution should be taken when generalizing results from these 
countries.  
The final limitation relates to measurement. Costs were self-reported and in most cases 
likely estimated, such that there is likely much measurement error. Moreover, there are no 
international accounting standards for program-level costing. Therefore, it was not considered 
appropriate to compare costs across countries (moreover given the variation in disease burden 
and severity, the likely variation in CR dropout rates, etc. by country). The cost items in the 
survey were not sufficiently detailed to capture what types of costs respondents included in their 
estimates (e.g., capital, overhead, how human resource costs are partitioned on a per patient 
basis). Additionally, costs were likely considered differently depending on the health system in a 
given country (e.g., budgeted values, charges or billing data, or actual total or marginal costs). 
However the $1500PPP cost is consistent with delivery costs in Canada and the United Kingdom 
for example, and hence the data appear reasonable. Future research is needed to better 
characterize unit costs of CR delivery globally. On a related note, mean healthcare expenditure 
values used to put the costs in context were not available post-2014, yet data were collected in 
2016.  
Conclusion 
 Where available, CR is most often funded by public sources, but in 60% of programs, 
patients pay all or part of the cost OOP (on average half of the program cost or over $600PPP). 
The $1500 cost to treat one patient was driven primarily by personnel, exercise equipment and 
exercise stress testing costs, and varied by funding source in HICs. Funding source was also 
related to program capacity, patients per session, number of personnel (including physicians), 
and the type of functional capacity test used. Public (including hybrid) funding for CR had 
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distinct advantages. Task-shifting, use of functional walk tests, exercising more patients per 
session, not monitoring with telemetry and offering CR in alternate/unsupervised settings can 
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Supplementary Figure 1. Degree to which financial resources serve as barriers to cardiac 




Rating scale from 1=“not an issue” to 5 “major issue”.  





























Table 1: Patients Paying for CR, as well as Cost to Deliver CR Juxtaposed by Mean Healthcare Expenditure Per Capita, by Country 
with CR and Country Income Classification, N=1082 
Income Classification 
Country 
n Proportion of 
Program Cost 
Patient Pays  
(Mean ± SD %) 
Direct Cost to Patient 
(2016 PPP†) 
Mean ± SD 
Cost to Deliver CR to 
1 Patient (2016 
PPP†)§ 
Mean ± SD 
Healthcare Expenditure 
per Capita in 2014 
PPP[47] (CR proportion)  
High-Income      
Australia 85 37.33 ± 54.42 $144.88 ± $280.41 $1023.99 ± $602.76 $6031.11 (16.98%) 
Austria 5 _ _ $5668.26 ± $421.90 $5580.49 (101.57%) 
Bahrain 1 0 NA _ $1242.84 
Barbados 1 0  NA _ $1146.04 
Belgium 9 9.70 ± 6.83 $317.77 ± $231.50 $1951.81 ± $945.05 $4839.83 (40.33%) 
Bermuda 1 _ _ $7,073.00 n/a 
Canada 55 33.23 ± 38.66 $275.29 ± $194.68 $938.29 ± $563.81 $5291.74 (18.58%) 
Chile 1 50.00  $100.00  $100.00  $1137.35 (8.79%) 
Croatia 3 17.00 ± 0.00 $73.44 ± 0.00 $346.40 ± $158.28 $1050.33 (32.98%) 
Czech Republic 6 50.00 ± 0.00 $185.82 $3493.38 $1378.52 (253.42%) 
Curaçao  1 _ _ $586.00  _ 
Denmark 1 0 NA $1960.53  $6463.24 (30.33%) 
Estonia 2 0 NA $938.63 ± $0.00 $1248.28 (75.19%) 
Finland 11 0 NA $984.66 ± $894.82 $4612.29 (21.34%) 
France 16 0 NA $4598.05 ± $2066.49 $4958.99 (92.72%) 
Germany 34 12.82 ± 25.97 $734.14 ± $700.61 $2427.81 ± $977.11  $5410.63 (44.87%) 
Greece 4 100.00 ± 0.00 $3114.75 ± $231.84 $1967.21 ± $1614.57 $1743.04 (112.85%) 
Hungary 20 0 NA $1467.41 ± $183.66 $1036.62 (141.56%) 
Iceland 4 56.00 ± 26.51 $309.45 ± $152.01 $2369.77 ± $3754.25 $4661.62 (50.84%) 
Ireland 6 0 NA $716.33 ± $0.00 $4239.15 (16.90%) 
Israel 6 15.00 ± 21.21 100.00 $1450.00 ± $1100.00 $2919.29 (49.67%) 
Italy 68 47.20 ± 39.64 $1675.00 ± $2238.71 $4375.73 ± $2111.61 $3257.75 (134.32%) 
Japan 9 0 NA $396.00 ± $434.46 $3702.95 (10.69%) 
Latvia 1 13.00  $262.10  $2096.77  $920.70 (227.74%) 
Lithuania 9 0 NA $1400.29 ± $467.15 $1063.42 (131.68%) 
Netherlands 29 15.00 _ $1662.51 ± $1297.79 $5693.86 (29.20%) 
New Zealand 27 100.00 ± 0.00 $491.19 ± $129.35 $557.81 ± $740.05 $4896.35 (11.39%) 
Northern Ireland 10 0 NA $859.60  n/a 
Poland 20 0 NA $1507.98 ± $810.68 $910.28 (165.66%) 
Portugal 20 53.20 ± 44.17 $694.99 ± $1277.56 $789.93 ± $610.14  $2096.82 (37.67%) 
Qatar 1 0 NA _ $2106.35 
Russian Federation 3 0 NA _ $892.85 
Scotland 23 60.00  _ $778.65 ± $502.25 $3934.82 (19.79%) 
Singapore 7 45.00 ± 37.75 $263.87 ± $247.23 $226.37 ± $93.86 $2752.32 (8.22%) 
Slovak Republic 1 95.00 $374.22  $374.22 $1454.81 (25.72%) 
Slovenia 2 75.00 $383.97 $1277.13 ± $1263.11 $2160.75 (59.11%) 
South Korea  12 98.18 ± 6.03 $681.03 ± $445.72 $820.20 ± $429.63 $2060.25 (39.81%) 
Spain 47 _ $2470.06 ± $740.98 1679.14 ± $1466.69 $2658.27 (63.17%) 
Sweden 1 0 NA _ $6807.72 
Switzerland 4 _ _ $1601.83 ± $1189.05 $9673.52 (16.56%) 
Taiwan 22 9.83 ± 1.36 $151.53 ± $45.11 $894.14 ± $775.41 n/a 
United Kingdom 57 66.5 ± 47.37 $157.59 $731.54 ± $220.07 $3934.82 (18.59%) 
United States 65 15.78 ± 8.45 $1272.00 ± $2291.59 $5016.60 ± $2723.11 $9402.54 (53.35%) 
Uruguay 5 75.00 ± 28.87 $722.56 ± $1035.39 $148.16 ± $97.73 $1442.27 (10.27%) 
Wales 15 _ $35.82  $1002.87 _ 
HIC Mean ± SD  40.67 ± 38.87 $675.49 ± $1178.54 $1865.48 ± $1857.57 $3420.37 ± $2315.79 
HIC Median  
(Q25-Q75) 










     
Afghanistan 1 0 NA _ $56.57 
Algeria 1 _ _ _ $361.73 
Argentina 3 75.00 ± 35.35 $47.50 ± $10.61 $1200.00 $605.19 (198.28%) 
Bangladesh 1 20.00  $336.38  $336.38  $30.83 (1091.08%) 
Belarus 1 0 NA _ $450.21  
Bosnia and Herzegovina 1 20.00  $175.95  $879.77  $463.64 (189.75%) 
Brazil 29 77.5 ± 36.15 $1262.22 ± $453.69 $844.57 $947.43 (89.14%) 
Brunei Darussalam 2 0 NA _ $957.60 
Bulgaria 1 0 NA _ $661.85 
China 81 40.82 ± 30.00 $618.37 ± $672.60 $706.75 ± $734.16 $419.73 (168.38%) 
Colombia 47 14.33 ± 7.68 $132.92 ± $141.53 $833.96 ± $597.59 $569.18 (146.52%) 
Costa Rica 6 _ $867.38 ± $802.39 $300.00  $970.00 (30.93%) 
Cuba 8 0 NA $45.28 $816.62 (5.54%) 
Dominican Republic 1 15.00  _ $3549.61  $268.99 (1319.60%) 
Ecuador 2  _ $450.00  $900.00 ± $848.53 $579.19 (155.39%) 
Egypt 2 20.00 $150.00 _ $177.77 
Georgia 11 83.75 ± 29.61 $749.86 ± $540.81 $729.53 ± $284.76 $302.60 (241.09%) 
Guatemala 2 10.00 $89.57 _ $232.62 
Honduras 1 _ _ $300.00  $212.31 (141.30%) 
India 18 90.78 ± 23.87 $357.61 ± $195.55 $1027.12 ± $2030.27 $74.99 (1369.68%) 
Indonesia 9 21.67 ± 25.66 $541.20 ± $327.06 $276.05 ± $14.21 $99.41 (277.69%) 
Iran 14 29.82 ± 18.08 $249.16 ± $343.18 $1906.88 ± $2947.68 $350.74 (543.67%) 
Jamaica 1 _ _ _ $266.19 
Kazakhstan 1 _ _ _ $538.78 
Kenya 1 100.00  $1598.30  $1598.30  $77.69 (2057.28%) 
Lebanon 1 80.00  $1000.00  $1000.00  $568.71 (175.84%) 
Macedonia 1 _ _ $6116.21 $353.92 (1728.13%) 
Malaysia 4 25.00 ± 22.91 $255.63 ± $72.30 $749.83 ± $379.53 $455.82 (164.50%) 
Malta 1 0 NA _ $2470.59 
Mauritius 1 _ _ _ $482.45 
Mexico 9 84.17 ± 29.39 $2400.41 ± $1919.58 $1808.92 ± $1955.39 $677.19 (267.12%) 
Moldova 1 0 NA $944.80  $228.85 (412.85%) 
Morocco 1 _ _ _ $190.05  
Mongolia 1 _ _ _ $195.33 
Nepal 1 0 NA _ $39.87 
Nigeria 1 90.00 _ _ $117.52 
Pakistan 2 100.00 $171.35  $171.35 $36.15 (473.99%) 
Panama 1 _ $108.00  _ $958.98 
Paraguay 3 50.00 $325.00 ± $247.49 $400.00 $464.09 (86.19%) 
CR, cardiac rehabilitation; SD, standard deviation; USD, United States Dollars; Q25-Q75, 1st- 3rd quartile  
§this item assessed total program costs (i.e., not itemized) and hence was likely estimated grossly by respondents. Therefore 
there is likely considerable measurement error which should be taken into consideration when interpreting the values. 
Peru 7 100.00 $1584.28 $883.39 ± $991.20 $358.58 (246.36%) 
Philippines 10 100.00 ± 0.00 $764.27 ± $297.64 $485.60 ± $198.47 $135.20 (359.17%) 
Romania 2 _ _ $532.94 $556.81 (95.71%) 
Serbia 2 0 NA $868.71 ± $354.25 $632.92 (137.25%) 
South Africa 14 53.00 ± 41.91 $1251.08 ± $1063.39 $1716.99 ± $1474.63 $570.21 (301.11%) 
Sri Lanka 1 0 NA _ $127.33 
Tunisia 1 66.00  $2853.07  $2139.80  $305.30 (700.88%) 
Turkey 9 0 NA $1549.36 ± $576.87 $567.63 (272.95%) 
Venezuela 8 85.00 ± 23.80 $391.50 ± $256.95 $2972.29 ± $1978.09 $873.38 (340.32%) 
LMIC Mean ± SD  49.60 ± 38.30 $597.25 ± $783.03 $1038.26 ± $1202.81 $455.39 ± $401.28 
LMIC Median  
(Q25-Q75) 








Global Mean± SD  46.13 ± 38.70 $626.07 ± $946.33 $1527.84 ± $1671.11 $1803.11 ± $2166.96 
Global Median 
 (Q25-Q75) 








†PPP, Purchasing Power Parity (http://eppi.ioe.ac.uk/costconversion/default.aspx) 
- Response about CR cost was not provided by any respondent in the country  
NA – not applicable as patients do not pay for any part of CR in this country 
n/a not available 
 
Table 2: Impact of Cardiac Rehabilitation Funding Source 
 






Hybrid All  
Any Patient 
Funding 
Program capacity (patients / 
year) 
522.46 ± 887.86 
‖‖ 
534.46 ± 923.20 
† 
     
   926.98 ± 1661.00 
‖‖ 
† 
627.32 ± 1151.93 
** 
     
768.41 ± 1473.59 
* 
 











Number healthcare providers on 
team  




6.15 ± 3.10 
 
5.88 ± 2.81 
* 
5.61 ± 2.82 
** 
Physician on team (% yes) 210 (40.50%)  80 (46.20%) 124 (52.80%) 414 (44.70%) 174 (49.00%) 
Staff-to-patient ratio 
 
1:5.15 ± 9.45 1:3.52 ± 3.19 
 
1:5.07 ± 7.31 
 
1:4.81 ± 8.04 
 
1:4.29 ± 6.11 
 











Patient receives individual 











Program uses cardiopulmonary 
stress tests (VO2) 









Number risk factors assessed 
(/12) 
8.48 ± 3.59 8.35 ± 3.69 8.79 ± 3.52 8.54 ± 3.59 8.87 ± 3.29 
Core components delivered (/10) 7.24 ± 2.98 6.93 ± 2.92 7.33 ± 2.83 7.21 ± 2.93 7.27 ± 2.64 
** 
Patients monitored during 
exercise with telemetry (% yes) 
244 (48.70%)  97 (57.10%) 170 (73.00%) 511 (56.50%) 236 (67.00%) 
Patients per exercise session 9.95 ± 5.75 
††† 
6.10 ± 5.41 
††† 
‖‖‖ 
9.28 ± 5.31 
‖‖‖ 
 
9.04 ± 5.76 
*** 
7.80 ± 5.59 
     Median (Q25-Q75) 9.00 (6.00-12.00) 5.00 (2.00-8.00) 8.00 (5.00-12.00) 8.00 (5.00-12.00) 6.00 (4.00-10.00) 
CR dose (hours) 33.09 ± 48.70 42.11 ± 55.07 41.05 ± 60.11 37.03 ± 53.27 40.77 ± 53.71 











Program offers alternative 
models (% yes) 
194 (38.60%) 38 (22.10%) 51 (21.80%) 283 (31.20%) 81 (22.80%) 
§median and 1st- 3rd quartile (Q25-Q75) shown where variation high (i.e., standard deviations greater than means). 
Compared by funding source using Generalized Linear Mixed model adjusting for country – one model for each row.  
* p<.05; ** p<.01; *** p<.001 for Generalized Mixed Models testing for overall model significance  







Table 3: Drivers of Program Delivery Costs, by Country Income Classification 
 
Driver 
n (%) or  
mean ± standard deviation (median) 
High-Income 
(n=749) 




Funding source ($2016PPP‖)  0.003  0.07 
   Public $1981.20 ± 1962.69  
($1306.73) 
 $1262.69 ± 1275.21 
($1012.04) 
 
   Private (incl. patients) $1051.22 ± 963.02 
($582.66) 
 $1200.29 ± 1291.33 
($828.13) 
 
  Hybrid $2084.86 ± 1898.54 
($1513.24) 
 $780.38 ± 1036.84 
($517.65) 
 
          Patients (full or partial) 184 (24.90%) <0.001 211 (65.30%) 0.35 
 Yes $1399.21 ± 1554.68 
($797.87) 
 $998.77 ± 1207.05 
($641.64) 
 
 No $2054.81 ± 1939.76 
($1408.45) 
 $1176.54 ± 1199.78 
($998.29) 
 
Program capacity (patients / year) 537.48 ± 809.79 
(300.00) 
0.005 806.56 ± 1623.82 
(300.00) 
<0.001 
Number healthcare providers on team§ 5.91 ± 2.78 (5.50) 0.001 5.81 ± 2.85 (5.50) 0.002 
Physician on team (% yes) 227 (36.30%) 0.006 188 (61.20%) 0.06 
      Yes $2486.99 ± 1914.59 
($1960.53) 
 $1168.82 ± 1403.41 
($731.48) 
 
      No $1158.00 ± 1403.94  
($716.33) 
 $798.66 ± 678.37 
($568.64) 
 
Staff-to-patient ratio 1:5.45 ± 9.58  
(1:4.00) 
0.19 1:3.51 ± 2.69 
(1:3.00) 
0.52 
Patient receives individual consult with physician (% yes) 303 (54.30%) 0.001 253 (93.00%) 0.85 
     Yes $2158.57 ± 1905.31 
($1668.08) 
 $980.50 ± 1095.68 
($702.22) 
 
     No $1190.50±1602.96  $822.38 ± 786.76  
($716.33) ($474.55) 
Program has cardiopulmonary stress tests (VO2) (% yes) 403 (63.50%) 0.002 253 (83.80%) 0.33 
     Yes $1942.74 ± 1774.64 
($1440.64) 
 $1098.10 ± 1288.65 
($836.35) 
 
     No $1281.36 ± 1806.42 
($716.33) 
 $810.01 ± 773.99 
($585.19) 
 
Core components delivered (/10) 8.23 ± 1.59 
(8.50) 
0.01 7.68 ± 1.75 
(8.00) 
0.87 
Patients monitored during exercise with telemetry (% yes) 341 (56.10%) 0.01 172 (57.00%) 0.26 
   Yes $2199.64 ± 2050.47 
($1445.78) 
 $943.72 ± 1040.08 
($701.94) 
 
   No $1147.22 ± 1043.09 
($828.50) 
 $1126.70 ± 1384.41 
($718.23) 
 
Number patients per exercise session 9.68 ± 5.55 
(8.50) 
0.71 7.77 ± 6.08 
(6.00) 
<0.001 
CR dose (hours) 35.93 ± 57.44 0.87 39.65 ± 43.51 0.68 
(22.50) (30.00) 
Program offers alternative models (% yes) 219 (36.00%) 0.38 66 (21.50%) 0.02 
   Yes $1588.30 ± 1867.82 
($800.00) 
 $684.68 ± 605.38 
($431.41) 
 
   No $1956.69 ± 1790.90 
($1516.44) 
 $1122.69 ± 1305.00 
($731.48) 
 
‖ PPP, Purchasing Power Parity (http://eppi.ioe.ac.uk/costconversion/default.aspx) 
§part-time staff counted as .5.   
†association with cost to deliver CR to 1 patient, using generalized linear mixed model adjusting for country.  
 
 
Supplementary Table 1: Perceived expense of elements to deliver cardiac rehabilitation 
 
Mean ± Standard Deviation‖ 
High-Income 
(n=747) 




Front-line personnel 3.51 ± 1.25 2.83 ± 1.10 3.29 ± 1.24** 
Exercise equipment 3.13 ± 1.21 3.49 ± 1.24 3.25 ± 1.23 
Exercise stress testing  3.21 ± 1.33 3.27 ± 1.17 3.23 ± 1.28 
Equipment/supplies for CVD risk assessment  2.84 ± 1.12 3.10 ± 1.20 2.93 ± 1.15 
Space 2.76 ± 1.32 2.85 ± 1.28 2.79 ± 1.30 
Patient education material 2.29 ± 0.89 2.36 ± 0.97 2.31 ± 0.92 
Blood pressure assessment device 2.27 ± 0.82 2.16 ± 0.93 2.23 ± 0.86 
Blood collection and lipid testing 2.42 ± 1.00 2.63 ± 1.03 2.50 ± 1.02† 
Resistance training equipment  2.44 ± 0.91 2.56 ± 0.98 2.48 ± 0.93 
CVD, Cardiovascular disease 
‖scores range from 1=“free” to 5=”very expensive” 
***p<.01.  
†trend, p=.08 
§ Compared by country income classification using generalized linear mixed model adjusting for country – one model for each 
row.  
 
